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ABSTRACT
Background: Adherence to American College of Chest Physicians (CHEST) and National Com-
prehensive Cancer Network (NCCN) guidelines for venous thromboembolism (VTE) prophy-
laxis helps avoid thromboembolic complications during hospitalization. Electronic health records 
(EHR) have the potential to make an impact on guideline adherence, but data are lacking. 
Objectives: To determine compliance with VTE prophylaxis guidelines in internal medicine and 
oncology populations and to determine whether EHR implementation had any effect on the rate 
and appropriateness of prophylaxis practices.
Methods: A retrospective chart review was conducted on medical and oncology patients admitted 
to the hospital for a 2-month period pre-EHR and post-EHR implementation. Risk assessment 
tools were available pre and post, however they were not mandatory. The rate of VTE prophylaxis 
was compared between the 2 time periods, with appropriateness assessed in a subgroup of partici-
pants without prophylaxis. 
Results: A total of 2,423 patients on the oncology and internal medicine floors were identified 
during the pre-EHR (n = 1,171) and post-EHR (n = 1,252) time periods. Patients in the post-EHR 
group were less likely to be prescribed prophylaxis as compared to those in the pre-EHR group 
(43% vs 50%; P = .001). In the patients audited for proper prophylaxis use (n = 750), significantly 
more patients in the post-EHR group had risk factors (84% vs 53%; P < .001) and contrain-
dications (23% vs 8%; P = .001) than in the pre-EHR group. Noncompliance to prophylaxis 
in patients who were candidates (positive risk factors without contraindications) occurred more 
often in the post-EHR group (51% vs 39%; P < .001). 
Conclusion: Implementation of an EHR was associated with an increase in the documentation of 
risk factors and contraindications; however, there was a significant decrease in VTE prophylaxis 
utilization after EHR implementation.
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Venous thromboembolism (VTE) is a com-mon occurrence in both internal medicine and oncology patients, and VTE during 
hospitalization accounts for one-fourth of all VTE 
events.1 Hospitalization alone is associated with an 
8-fold increased risk of VTE, and 50% to 75% of 
these events occur in patients on the internal medi-
cine floor.1 In a study of 1,180 inpatients, of whom 
60.3% were categorized as low risk and 39.7% as 
high risk, it was found that VTE occurred in 11% 
of high-risk patients who did not receive prophy-
laxis. Only 0.3% of low-risk patients who did not 
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receive prophylaxis experienced a VTE (hazard 
ratio [HR], 32.0; 95% CI, 4.1-251.0).2 
The American College of Chest Physicians (ACCP) 
recommends the Padua Prediction Score to assign risk 
stratification for VTE in hospitalized internal medicine 
patients to either high or low risk.1 This stratification is 
based on factors such as active cancer, previous VTE, 
reduced mobility for at least 3 days, known thrombo-
philic condition, recent trauma, recent surgery, heart 
failure, respiratory failure, acute myocardial infarc-
tion, acute ischemic stroke, acute infection, obesity, 
and ongoing hormonal treatment.2 Because cancer is 
a major risk factor, oncology patients are at an even 
greater risk of VTE during hospitalization; 3% to 12% 
experience VTE in their first hospitalization.3 VTE 
increases the likelihood of death by 2- to 6-fold and is 
the most common cause of death at 30-day follow-up 
in cancer patients undergoing surgery.3 The National 
Comprehensive Cancer Network guideline identifies 
additional risk factors based on cancer- and treatment-
related factors. The specific cancers with the highest risk 
include pancreatic, brain, stomach, kidney, uterus, lung, 
ovary, bladder, and testis tumors. Treatment with cer-
tain antineoplastic (diethylstilbestrol, thalidomide, or 
lenalidomide) and hormonal compounds is also associ-
ated with an increased VTE risk in patients with cancer.
The risk for VTE must outweigh the risk of 
a major bleeding event in order for a patient to 
receive prophylaxis. For internal medicine patients, 
the major risk factors for a major bleeding event are 
active gastroduodenal ulcer, bleeding in the 3 months 
before admission, and platelet count less than 50 x 
109/L.1 Oncology patients are typically at a higher 
risk of bleeding than internal medicine patients. In 
one study comparing 181 oncology patients and 661 
non-oncology patients all receiving VTE prophylaxis, 
the 12-month cumulative incidence of major bleeding 
was 12.4% and 4.9%, respectively.4 
With the implementation of electronic health 
records (EHRs) and the ability to create VTE prophy-
laxis order sets, there is a more uniform and easily 
accessible way for physicians to order anticoagula-
tion for their patients. To date, there are no studies 
that have examined the impact of EHR implementa-
tion on VTE prophylaxis. 
The objective of this study was to  determine 
 compliance with VTE prophylaxis guideline  recom - 
mendations in the internal medicine and  oncology 
populations, and to determine whether the imple-
mentation of an EHR has any effect on the rate and 
appropriateness of exclusion of VTE prophylaxis use at 
St.  Vincent Indianapolis Hospital. Our customizable 
EHR includes computer physician order entry and 
an electronic medication administration record with 
barcode verification. During the study period, the 
EHR was not used routinely for physician documen-
tation, however it was used for allied health services 
documentation.
METHODS
A retrospective, institutional review board–
approved chart review was completed to meet the 
study objectives. All medical and oncology patients 
admitted to a community teaching hospital in a 
2-month period pre-EHR implementation (Novem-
ber 1, 2011 to December 31, 2011) and a 2-month 
period post-EHR implementation (November 1, 2012 
to December 31, 2012) were evaluated for compliance 
with VTE prophylaxis guidelines. The EHR was imple-
mented in February 2012, allowing for a 9-month lead 
in period prior to evaluation of the post-EHR period. 
Patient treatment was classified as either compliant 
or noncompliant based on the CHEST guidelines for 
nonsurgical internal medicine patients and the NCCN 
guidelines for oncology patients (Table 1). 
Compliance rates were compared between the 
2 groups to determine whether the implementa-
tion of the EHR had any effect on the use of proper 
VTE prophylaxis. This compliance rate was calcu-
lated based on the entire population (pre-EHR and 
post-EHR). If a patient was prescribed VTE prophy-
laxis, it was assumed to be appropriate. A random 
sampling of 750 patients without prophylaxis, split 
between the 2 groups, was conducted to further 
determine the appropriateness of the lack of phar-
macologic prophylaxis. Each patient eligible for 
evaluation was assigned a number, and our sample 
was determined using a random number generator. 
Electronic and paper charts were manually evaluated 
for the study endpoints in this sampling of patients. 
Patients were labeled as candidates for pharmaco-
logic prophylaxis if they had positive risk factors for 
VTE without contraindications to pharmacologic 
prophylaxis. Contraindications to pharmacologic 
prophylaxis were based on drug, patient, and spe-
cific guideline factors (Table 2).
Eligibility Criteria
The study included all patients admitted to the 
oncology unit with an oncology diagnosis or seen by 
an oncology attending physician or patients admit-
ted to the internal medicine units during the 2-month 
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Table 1. Recommended venous thromboembolism prophylactic regimens for hospitalized patients
Internal medicine population
Increased thrombosis risk Low thrombosis risk Contraindications to pharmacologic  
prophylaxis
Enoxaparin 40 mg SQ daily
Enoxaparin 30 mg SQ q12h
Enoxaparin 30 mg SQ daily (in renal 
impairment)
Fondaparinux 2.5 mg SQ daily
UFH 5000 units q8-12h
None Graduated compression stockings
Intermittent pneumatic compression
Oncology population
Without contraindications to  
pharmacologic prophylaxis
With contraindications to pharmacologic prophylaxis
Enoxaparin 40 mg SQ daily
Enoxaparin 30 mg SQ daily if CrCl <  
30 mL/min
Fondaparinux 2.5 mg SQ daily
UFH 5,000 units SQ q8-12h
Graduated compression stockings
Intermittent pneumatic compression
Note:  CrCl = creatinine clearance; SQ = subcutaneous; q = every; UFH = unfractionated heparin. 
Table 2. Oncology and internal medicine patients: Contraindications to prophylaxis
Anticoagulation Mechanical 
•   CNS bleed, intracranial bleed, or spinal lesion at high  
risk for bleeding within 30 days
•  Active major bleeding (more than 2 units transfused  
in 24 hours)
•  Spinal anesthesia/lumbar puncture
•  Chronic, clinically significant measurable bleeding > 48  
hours
•  Platelets < 50,000/mcL
•  Severe platelet dysfunction
•  Major operation at high risk for bleeding within 24 hours
•  Underlying coagulopathy
•  Acute DVT
•  Large hematoma
•  Skin ulceration or wounds
•  Platelets < 20,000/mcL or petechiae
•  Severe arterial insufficiency (GCS only)
•  Mild arterial insufficiency (GCS only)
•  Peripheral neuropathy (GCS only)
Note:  CNS = central nervous system; DVT = deep vein thrombosis; GCS = graduated compression stockings.
periods. Patients excluded were those younger than 
18 years old, prisoners, and pregnant women.
Data Collection
Data collected included hospital room number, 
age, sex, receipt of anticoagulants, and receipt of 
mechanical VTE prophylaxis. Patients were evaluated 
to determine whether or not they received pharmaco-
logic VTE prophylaxis. Subsequently, data were col-
lected in a random sampling of patients not receiving 
pharmacologic prophylaxis and included demograph-
ics (pertinent diagnosis, history of bleeding and/or 
clotting disorders, age, sex, height, weight), indications 
for VTE prophylaxis, renal function (serum creatinine 
144 Volume 51, February 2016
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and creatinine clearance as calculated by the Cock-
croft-Gault equation), use of mechanical prophylaxis, 
risk factors for VTE, and contraindications for phar-
macologic VTE prophylaxis. This random sampling 
was evaluated to determine whether there was an 
appropriate reason for not initiating pharmacologic 
prophylaxis per CHEST and NCCN guidelines. 
Data Analysis
The primary endpoint of the study was to deter-
mine the rates of VTE prophylaxis (pharmacologic 
or mechanical) pre- and post-EHR implementation. 
Secondary endpoints included the rate of noncompli-
ance with pharmacologic prophylaxis (risk factors 
for VTE present, no contraindications present) in a 
random sampling of patients not receiving pharma-
cologic prophylaxis and the rate of risk factor and 
contraindication documentation. Subgroup analy-
ses based on service (hematology/oncology, internal 
medicine, other) were conducted utilizing the above 
outcomes. Patients were placed into 2 groups (pre- 
and post-EHR implementation), and data were com-
pared via the chi-square test for nominal data and 
Mann-Whitney U test for continuous, nonparametric 
data. Data were tested for normality via the Shapiro-
Wilk test. Data were evaluated using IBM SPSS, ver-
sion 22 (IBM Corp., Armonk, NY).
RESULTS 
A total of 2,475 patients on the oncology and 
internal medicine floors were identified. Fifty-two 
patients were excluded due to incomplete data, 
which left an included population of 2,423 during 
the pre-EHR (n = 1,171) and post-EHR (n = 1,252) 
time periods. Overall, the median age of the popula-
tion was 63 years, and the majority of the population 
was female (57% in the pre- and post-EHR groups). 
Prophylaxis (mechanical and pharmacologic) was 
utilized in 584 (50%) of the pre-EHR group and 539 
(43%) of the post-EHR group (P < .0001) (Table 3). 
In the analysis of the random sampling of 
patients receiving no pharmacologic prophylaxis 
(n = 750), 195 (53%) of the pre-EHR patients and 
326 (85%) of the post-EHR patients had risk fac-
tors present that made them candidates for VTE pro-
phylaxis (P < .001). Of these patients, 30 (10%) in 
the pre-EHR group and 90 (23%) in the post-EHR 
group had contraindications to pharmacologic pro-
phylaxis (P < .001). Candidates for pharmacologic 
prophylaxis without contraindications who did not 
receive prophylaxis included 142 (39%) patients in 
the pre-EHR group and 195 (51%) patients in the 
post-EHR group (P < .001). Candidates for pharma-
cologic prophylaxis receiving mechanical prophy-
laxis were 34 (24%) in the pre-EHR group and 61 
(31%) in the post-EHR group (P < .001) (Table 4).
In the internal medicine subgroup of patients not 
receiving pharmacologic prophylaxis (n = 431; 185 
pre-EHR, 246 post-EHR), risk factors were present 
in 75 (41%) and 204 (83%) patients in the pre- and 
post-EHR groups, respectively (P < .001) (Table 4). 
Statistically significant differences in the contraindi-
cations present before and after EHR implementation 
were found within the internal medicine subgroup 
(6.5% vs 27%; P < .001). Patients who were VTE 
candidates based on positive indications for pharma-
cologic prophylaxis without contraindications were 
less prevalent in the pre-EHR group than the post-
EHR group (24% vs 45%; P < .001).
Likewise, in the hematology/oncology subgroup 
of patients not receiving pharmacologic prophylaxis 
(n = 186; 97 pre-EHR, 89 post-EHR), 64 (66%) 
patients in the pre-EHR group and 84 (94%) patients 
in the post-EHR group had risk factors present 
(P < .001), while 13 (13%) and 19 (21%) had 
 contraindications, respectively (P = .151) (Table 
Table 3. Demographics of patients identified for study inclusion: Pre- and post-implementation of electronic 
health records (EHRs)
Demographics Pre-EHR Post-EHR P value*
No. of participants 1,171 1,252
Received pharmacologic VTE prophylaxis 584 (50%) 539 (43%) <.001
No pharmacologic VTE prophylaxis received 587 (50%) 713 (57%)
Age, median years (IQR) 63 (29) 63 (29) .621
Male 505 (43%) 541 (43%) .97
Note:  EHR = electronic health record; IQR = interquartile range; VTE = venous thromboembolism.
*Level of significance: P < .05, chi-square test. 
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4).  Candidates for pharmacologic prophylaxis 
without contraindications who did not receive 
prophylaxis included 47 (48%) patients and 57 
(64%) patients in the pre- and post-EHR groups, 
respectively (P = .032). 
DISCUSSION
The results of this study indicate that the imple-
mentation of an EHR at a community teaching 
hospital was associated with a decrease in the use 
of VTE prophylaxis. Before this study, no studies 
evaluated the compliance rates of VTE prophylaxis 
before and after EHR implementation. There are 
data supporting the utilization of clinical decision 
support tools (CDST) within the EHR and their 
impact on VTE prophylaxis compliance.5-7 Haut 
and colleagues conducted a study to examine docu-
mentation and compliance to guidelines in a trauma 
population before and after a mandatory risk factor 
stratification tool and orderset.6 They found that 
both documentation and compliance increased fol-
lowing implementation (3% vs 97.8% and 66.2% 
vs 84.4%, respectively; P < .001). Novis and col-
leagues found a significant increase in compliance 
in a surgical population, however not to the same 
extent as the study by Haut and colleagues (14% 
vs 36%; P < .001).4 Compared to the previous 
2 studies, MaCauley and associates evaluated VTE 
prophylaxis compliance rates in a broader patient 
population that included medicine patients.7 They 
Table 4. Sampling of patients not receiving pharmacologic VTE prophylaxis: Pre- vs postimplementation of 
electronic health records (EHRs)a
All patients Internal medicine population Oncology population
Pre-EHR Post-EHR P value* Pre-EHR Post-EHR P value* Pre-EHR Post-EHR P value*
N 366 384 — 185 246 — 97 89 —
Age, median years 
(IQR)
64 (28) 63 (28) .562 69 (33) 66 (31) .566 64 (28) 63 (28) .524
Male, n (%) 160 (44) 180 (47) .385 78 (42) 124 (50) .090 44 (45) 33 (37) .252
Receiving 
mechanical 
prophylaxis (IPC 
or GCS), n (%)
107 (29) 134 (35) .097 77 (42) 124 (50) .709 18 (19) 23 (26) .231
At least 1 risk 
factor present,  
n (%)
195 (53) 326 (84) <.001 75 (41) 204 (83) <.001 64 (66) 84 (94) <.001
Therapeutic 
anticoagulation, 
n (%)
71 (19) 71 (19) .751 44 (24) 54 (22) .653 20 (21) 10 (11) .082
Contraindications, 
n (%)
30 (8) 90 (23) <.001 12 (6.5) 66 (27) <.001 13 (13) 19 (21) .151
Candidates for 
pharmacologic 
prophylaxis, n (%)
142 (39) 195 (51) <.001 45 (24) 110 (45) <.001 47 (48) 57 (64) .032
Candidates for 
pharmacologic 
prophylaxis 
receiving 
mechanical 
prophylaxis, n (%)
34 (9) 61 (16) <.001 19 (10) 38 (15) .012 9 (9) 16 (18) .063
Note: EHR = electronic health record; GCS = graduated compression stockings; IPC = intermittent pneumatic compression; IQR = interquartile range; 
VTE = venous thromboembolism
aPatients included in this analysis are from a random sampling of patients included in the study and not receiving pharmacologic VTE prophylaxis.
*Level of significance: P < .05, chi-square test. 
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assessed VTE prophylaxis compliance rates in 
patients categorized as low risk from their clini-
cal decision support tool. Similar to surgical and 
trauma patient populations, there was a significant 
increase in the compliance rates after implementa-
tion (27% vs 34%; P < .0001). There is currently no 
published literature to support the use of CDST in 
the hematology and oncology population.
The VTE risk assessment tool and order set inclu-
ded in our EHR were not mandatory upon the imple-
mentation of the EHR, and this may explain the dif-
ferences in compliance rates between our study and 
published literature. This same assessment tool was 
available to be used both pre- and post-EHR imple-
mentation on either paper or in the EHR, respec-
tively. The assessment tool included a list of common 
risk factors for VTE and placed the patients into a 
low-, moderate-, or high-risk category. There was 
space available for documentation of contraindica-
tions to pharmacologic VTE prophylaxis on both 
versions. Upon further investigation, we discovered 
that the VTE risk assessment tool in the EHR was 
not provider-friendly during the study period. This 
may have led to decreased pharmacologic prophy-
laxis orders in our post-EHR time period. We tried 
to eliminate any initial EHR difficulties and growing 
pains by starting our post-EHR time period 8 months 
after the system was adopted. 
This was a single-center study with two, 
2-month time frames. Because the data were col-
lected over a short time frame, it is possible that 
many of the same physicians were working during 
both periods; the study may have missed the prac-
tice habits of physicians not on either service dur-
ing the 2-month period. This could have introduced 
bias into the results, because some physicians may 
be more likely than others to prescribe VTE pro-
phylaxis to their patients; however, it is unlikely 
that varying practice patterns would have resulted 
in a significant increase in the use of VTE prophy-
laxis. In future studies, it is recommended that data 
be collected over a longer period of time or that a 
random sampling of patients who were treated by 
different physicians be taken. 
The percentage of patients who received 
mechanical prophylaxis may be falsely high. Often 
times when mechanical prophylaxis is ordered, the 
patients refuse to wear them. That being said, that 
percentage of patients who did not receive any pro-
phylaxis, including mechanical, may be falsely low 
due to the possible lack to documentation of non-
compliance. Unless it was documented in a clinical 
note that a patient was not using mechanical pro-
phylaxis, we made the assumption that the patient 
was compliant.
Although rates of VTE prophylaxis decreased, 
after implementation of the EHR there was a sta-
tistically significant increase in the identification of 
contraindications to VTE prophylaxis and risk fac-
tors for development of VTE. We expected to see 
this increase but cannot conclude that the EHR 
makes it easier to identify risk factors and contra-
indications. Without further data collection on the 
entire population, we cannot determine whether the 
patient populations had similar baseline risk factors 
and contraindications or if the postimplementation 
group had a statistically significant difference in 
risk factors. Despite the increase in documented risk 
factors post-EHR implementation, the rate of pro-
phylaxis decreased. We were also unable to deter-
mine whether or not the physicians viewed the risk 
factors and contraindications or whether they were 
aware of all the risk factors and contraindications 
to prophylaxis. 
CONCLUSION 
Implementation of the EHR at a community 
teaching hospital was associated with a decreased 
overall rate and appropriateness of VTE prophylaxis 
practices and an increase in risk factor and contra-
indication documentation. The implementation of 
an EHR with computerized physician order entry 
in itself will not ensure an increase in VTE prophy-
laxis rates. The passive availability of an order set 
without a mandatory risk assessment followed by 
CDSTs allowed practice to continue unchanged with 
a decline in prophylaxis rates. To increase the likeli-
hood of success, CDSTs and mandatory assessment 
should be implemented within the EHR.
ACKNOWLEDGMENTS 
The authors declare no conflicts of interest. They 
thank Katherine Kielts, PharmD, Natalie Schwarber, 
PharmD, Joseph Tucker, PharmD, and Alicia Dethl-
off, PharmD, for their participation in the project.
REFERENCES 
1. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in 
nonsurgical patients: Antithrombotic therapy and prevention 
of thrombosis, 9th ed: American College of Chest Physicians 
evidence based clinical practice guideline. Chest. 2012;141(2 
suppl):e195S-e226S.
hpj5101142-148.indd   147 05/02/16   10:45 AM
VTE Prophylaxis Compliance and EMR Implementation
2. Barbar S, Noventa F, Rossetto V, et al. A risk assessment 
model for the identification of hospitalized medical patients 
at risk for venous thromboembolism: The Padua Prediction 
Score. J Thromb Haemost. 2010;8(11):2450-2457.
3. Streiff MB, Bockenstedt PL, Cataland SR. Venous throm-
boembolic disease. National Comprehensive Cancer Network 
website. http://www.nccn.org/professionals/physician_gls/pdf/
vte.pdf. February 2014. Accessed April 28, 2015.
4. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent 
venous thromboembolism and bleeding complications during 
anticoagulant treatment in patients with cancer and venous 
thrombosis. Blood. 2002;100:3483-3488.
5. Novis SJ, Havelka GE, Ostrowski D, et al. Prevention of 
thromboembolic events in surgical patients through the cre-
ation and implementation of a computerized risk assessment 
program. J Vasc Surg. 2010;51:648-654.
6. Haut ER, Lau BD, Kraenzlin FS, et al. Improved prophy-
laxis and decreased rates of preventable harm with the use 
of a mandatory computerized clinical decision support tool 
for prophylaxis for venous thromboembolism in trauma. Arch 
Surg. 2012;147(10):901-907.
7. MaCauley MJ, Showalter JW, Beck MJ, Chuang CH. The 
effect of a provider-enhanced clinical decision support tool for 
guiding venous thromboembolism pharmacoprophylaxis in 
low-risk patients. Hosp Pract. 2012;40(3):7-12. 
148 Volume 51, February 2016
hpj5101142-148.indd   148 05/02/16   10:45 AM
